Athithi Verma
The only FDA-cleared non-drug treatment for pediatric ADHD launched its second generation into a 1,500-family waitlist, with reimbursement still the open question.
IZCARGO, a therapy engineered to cross the blood-brain barrier, won its first marketing authorization outside Japan five years after launching there.
The European Commission approved Crysvita for infants as young as one month with XLH, a decision that also buys Kyowa Kirin two more years of orphan exclusivity.
Spain’s new draft Medicines Law will cut the price of generics and biosimilars automatically as their market share grows, replacing a system where prices froze after one initial discount.
A six-year-old with a rare genetic liver disorder became the first patient to receive a liver transplant through a single robotic incision, donated by his father.
A week defined by first-in-human starts across rare genetic disease, led by antisense entering Dravet syndrome from the field that already rewrote spinal muscular atrophy. Around it, first patients dosed in rare vascular and cardiomyopathy programs with near-empty competitive fields, a first-in-class readout in heparin-induced thrombocytopenia, and orphan designations that quietly reshape the economics behind them.
The Alzheimer’s Association International Conference drove the week’s pipeline news, but the signal that mattered most came from a lab: the first brain link that let one paralysed person move and feel through another. Around it, a tau target validated and contested in the same week, an oral entrant scaling in Huntington’s, and anti-amyloid therapy fighting its real battle, which is access.
Thirty four healthcare deals crossed the wire the week of July 13, 2026. Four of the five that matter paid cash for something that already works: an operating rare-disease pharmacy, an FDA-approved drug, a Phase 3 asset with Breakthrough.
Half of England’s heart failure patients have spent decades watching the other half get all the drugs. That’s the context for what NICE did this week. On 16 July, the institute published final draft guidance recommending finerenone for adults with chronic heart failure with preserved or mildly reduced ejection fraction. NICE estimates up to 280,000 … Read more
NICE recommended 66 new treatments last year and rejected seven but 25 evaluations were terminated before anyone ruled on them.